NervGen Pharma Corp.
NGEN.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -139.19% | 55.27% | -60.51% | 33.01% | -228.77% |
| Total Depreciation and Amortization | 4.12% | -14.16% | 5.61% | -2.73% | -61.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 989.61% | -112.57% | 8,775.65% | -101.47% | 384.09% |
| Change in Net Operating Assets | 131.53% | -53.35% | 246.28% | -219.53% | 134.16% |
| Cash from Operations | 7.69% | -9.77% | 38.02% | -38.07% | -26.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.41% | -2.22% | -2.70% | 203.28% | -- |
| Cash from Investing | 3.41% | -2.22% | -2.70% | 203.28% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 179.71% | 425.00% | 13.63% | 79.88% | -99.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.58% | -- | -- | 100.00% | 98.29% |
| Cash from Financing | 286.81% | 300.90% | 11.98% | 143.30% | -99.50% |
| Foreign Exchange rate Adjustments | 311.95% | 105.35% | -333.38% | -129.61% | 378.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 144.64% | 27.09% | 34.35% | -48.78% | -119.78% |